ASTRO

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
Monday, April 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

Astronergy upgraded its flagship 460W residential products with greener designs

Retrieved on: 
Thursday, April 25, 2024
VOC, Environment, European Economic Area, Organic compound, Topcon, ASTRO, Temperature, PERC, Hope, Carbon, Renewable energy

Earlier this year, Astronergy shipped the first over 43MW ASTRO N7s products to the EU Market, and more orders are under the manufacturing process.

Key Points: 
  • Earlier this year, Astronergy shipped the first over 43MW ASTRO N7s products to the EU Market, and more orders are under the manufacturing process.
  • Looking at the whole picture, with 460W power out and 23% conversion efficiency, newly upgraded greener and higher-aesthetics ASTRO N7s products could generate 20 to 45W greener power than other same-size PERC and TOPCon products, making the carbon emission recovery cycle of the product could be shortened by about 26%.
  • Acting as a responsible enterprise, Astronergy is striving to let more residents enjoy greener power and make home-use products lower carbon first.
  • In the future, greener products like the ASTRO N7s with green soul are expected for more scenarios.

American Urological Association Releases Salvage Therapy for Prostate Cancer Guideline

Retrieved on: 
Thursday, February 29, 2024
Therapy, Recurrence, Salvage therapy, Prostate cancer, Professor, ASTRO, Quality of life, Metastasis, Patient, Radiation, Risk, Society, University, AUA, SUO, Guideline, MPH, American Urological Association, Radiation therapy, Panel, Partnership, Medical imaging

BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.

Key Points: 
  • BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.
  • Understanding the evaluation and appropriate use of salvage therapies for patients with biochemical recurrence is a critical area of prostate cancer care.
  • “Thanks to the incredible expertise of the entire Panel, this guideline helps provide a roadmap that combines the latest advancements with thoughtful recommendations, empowering patients and clinicians alike.”
    This guideline has 30 recommendations and is a useful reference for effective evidence-based care related to salvage therapy for prostate cancer.
  • Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy.

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Neoplasm, Recurrence, ASTRO, Cancer, Society, Disease, HPV, Radiation therapy, Metastasis, DNA, Plasma

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.
  • "The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies.

World's first 43MW mass-production ASTRO N7s ZBB-TF n-type TOPCon products delivered to European market

Retrieved on: 
Wednesday, February 28, 2024
PV, Silicon, ASTRO, Topcon, ZBB, TF, Carbon, Certification, IEC, Gamer, Renewable energy

Certified by the IEC test, ASTRO N7s product has excellent anti-PID characteristics.

Key Points: 
  • Certified by the IEC test, ASTRO N7s product has excellent anti-PID characteristics.
  • Seeing the mass production and delivery of the first 43MW ASTRO N7s products, Astronergy hit another first in the industry to finish the marketization of such frontier products.
  • Through the mature ZBB-TF tech, fine-line silver fingers are printed on n-type TOPCon cells and narrow soldering copper ribbons are used at ASTRO N7s modules.
  • The abundant n-type tech strengths will consolidate Astronergy's position as a key player in shaping the future of solar power generation.

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024
Mohs surgery, Skin cancer, Freedom, Recurrence, Carcinoma, Toxicity, SRT, American Academy of Dermatology, Research, ASTRO, FDA, Skin, BCC, Radiation, SCC, NMSC, Society, Silverman, Patient, Histology, Photon, Radiation therapy, Cancer, American Academy, Medical imaging

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Thursday, January 18, 2024
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Neoplasm, National Comprehensive Cancer Network, Radiation therapy, Patient, Lymph node, Medicare, AAD, American Academy, Society, SCC, Metastasis, Journal, NCCN, ART, ASTRO

While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.

Key Points: 
  • While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.
  • In the study, normalized medical claims data identified 22,917 Medicare-eligible SCC patients in the United States who received ART in the 12 months ending June 2022.
  • Results from the study indicate that using the DecisionDx-SCC test to guide decisions about ART could result in net Medicare healthcare savings of up to approximately $972 million annually.
  • This outcome is based on the distribution of DecisionDx-SCC test results reported in previous studies, with cost reductions attributed to avoiding ART in patients with a DecisionDx-SCC low-risk, Class 1 test result and low rates of disease progression.

Online Video Remains the Growth Engine of Content Investment with Local Content Still Key to Acquiring Subscribers

Retrieved on: 
Monday, December 11, 2023
WPP plc, Smart TV, Marketing, ZEE5, FAST, Female, SVOD, AVOD, Media, AAMS, Travel, Shemaroo Entertainment, VOD, ASTRO, Akamai Technologies, Content, Development, Warner Bros. Discovery, EVP, CTV, CDNetworks, OTT, True Corporation, Product marketing, Network 10, CIO, Connected, Business development, Pacific Rim, Social media, Summit, Growth, UGC, Video game

Ex-China, online video revenues in Asia Pacific were expected to hit US$46 billion in 2028, up from US$29 billion this year.

Key Points: 
  • Ex-China, online video revenues in Asia Pacific were expected to hit US$46 billion in 2028, up from US$29 billion this year.
  • In terms of content trends and investment, although pay TV remained the largest vertical, online video was the growth engine of video content investment, with local and Asian content leading premium VOD viewership with the highest reach.
  • Hence local content remained key to acquiring subscribers in the region, and constantly over-indexing with new users.
  • A strong focus on content closed off the Summit, with panellists agreeing that Asian content could not be lumped together.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023
NDA, Cisplatin, Disclosure, Galera, Chronic kidney disease, Annual general meeting, Superoxide dismutase, ASN, ASTRO, Food, Type, SBRT, Head, Incidence, Investment, New Drug Application, Clinical trial, American Society of Nephrology, Insurance, Patient, Workforce, Research, Radiation therapy, Death, FDA, CKD, Neoplasm, LAPC, Therapy, Manganese, Enterocyte, GRECO, Cancer, CRL, Symantec Endpoint Protection, Combination, Superoxide dismutase mimetics, Layoff, Society, HNC, Poster, Pharmaceutical industry

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points: 
  • The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
  • Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
  • As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.